Stockscreener 앱 받기
0.5041
28.30%
0.1112
시장 영업 전:
.45
-0.0541
-10.73%
Vaxart Inc 주식(VXRT)의 최신 뉴스
Vaxart soars on positive data from new norovirus vaccine trial - MSN
Vaxart (VXRT) Shares Soar After Promising Norovirus Vaccine Tria - GuruFocus
Vaxart's Oral Norovirus Vaccine Pills Meet Primary Immunological Endpoint in Phase 1 Trial - marketscreener.com
Sector Update: Health Care Stocks Higher Pre-Bell Wednesday - marketscreener.com
Vaxart stock soars after positive Phase 1 norovirus vaccine results - Investing.com
Vaxart (VXRT) Unveils Promising Phase 1 Results for New Norovirus Vaccine | VXRT Stock News - GuruFocus
Vaxart reports improved antibody response in norovirus vaccine trial - Investing.com Australia
Vaxart Reports Positive Clinical Data Demonstrating that its Sec - GuruFocus
Vaxart Reports Positive Clinical Data Demonstrating Second-Generation Vaccine Technology Produces Stronger Antibody Responses Than First-Generation - marketscreener.com
Vaxart Reports Positive Clinical Data Demonstrating that - GlobeNewswire
Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology - Yahoo Finance
Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial | VXRT Stock News - GuruFocus
Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial - GlobeNewswire
Vaxart to Reveal First-Ever Oral Norovirus Vaccine Trial Results: Key Data Coming Tomorrow - Stock Titan
Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025 | VXRT Stock News - GuruFocus
Hagens Berman Sobol Shapiro LLP and Scott+Scott Attorneys at Law LLP Announce a Class Action for All Vaxart Shareholders that May Include You, Even if You Participated in the Previous Partial Settlement with Vaxart - Business Wire
Vaxart Announces Adjournment of Annual Meeting of Stockholders | - GuruFocus
Vaxart Announces Adjournment Of Annual Meeting Of Stockholders - marketscreener.com
Vaxart Announces Adjournment of Annual Meeting of Stockholders | VXRT Stock News - GuruFocus
Vaxart Annual Meeting Adjourned to June 13, 2025; Proxy Advisory Firms Support Proposal No. 2 - Nasdaq
Vaxart Announces Adjournment of Annual Meeting of Stockholders - GlobeNewswire
Vaxart Gets ISS and Glass Lewis Backing for Crucial Nasdaq Listing Vote as Deadline Nears - Stock Titan
Vaxart stock climbs on positive study of pill-based norovirus vaccine - MSN
Zoom Rises 8% in 3 Months: Here's Why You Should Buy the Stock Now - The Globe and Mail
Vaxart seeks shareholder nod for reverse stock split By Investing.com - Investing.com South Africa
Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025 - The Manila Times
Vaxart Leaders Set for Key Fireside Chat at Major Healthcare Conference: What to Expect - Stock Titan
Vaxart (VXRT) Releases Video Update Urging Support for Reverse S - GuruFocus
Vaxart seeks shareholder nod for reverse stock split - Investing.com Australia
Vaxart's Founder and Chief Scientific Officer Provides Video Update to Stockholders | VXRT Stock News - GuruFocus
Vaxart’s Founder and Chief Scientific Officer Provides Video Update to Stockholders - GlobeNewswire
Vaxart Founder Makes Urgent Appeal: Critical Nasdaq Compliance Vote Deadline Approaches - Stock Titan
Vaxart Discusses Reverse Stock Split and Capital Raise - TipRanks
Vaxart Answers Additional Frequently Asked Questions from Retail Investors - GlobeNewswire
Vaxart (VXRT) Addresses Stockholder Concerns Ahead of Annual Mee - GuruFocus
Vaxart Begins Phase 2b Trial for Oral COVID-19 Vaccine - TipRanks
Vaxart (VXRT) Addresses Stockholder Concerns Ahead of Annual Meeting | VXRT Stock News - GuruFocus
Vaxart Reveals New Split Ratio Details as Nasdaq Delisting Deadline LoomsCEO Urges Action - Stock Titan
USDJPY Faces An Intraday Corrective Recovery: Elliott Wave Intraday Analysis - The Globe and Mail
Vaxart (VXRT) Advances in Phase 2b Trial with Oral COVID-19 Vacc - GuruFocus
Vaxart Initiates Dosing In 10,000-Participant Portion Of Phase 2B Covid-19 Trial - marketscreener.com
Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial - GlobeNewswire
Vaxart (VXRT) Advances in Phase 2b Trial with Oral COVID-19 Vaccine | VXRT Stock News - GuruFocus
Breakthrough Oral COVID Vaccine Pill Advances: Vaxart Launches Massive 10,000-Patient Trial with $460M Backing - Stock Titan
RFK Jr issues bombshell order on Covid vaccine over safety concerns - MSN
Vaxart (NASDAQ:VXRT) Upgraded at Wall Street Zen - Defense World
Vaxart Urges Stockholder Action: Crucial Nasdaq Compliance Vote Delayed as Reverse Split Hangs in Balance - Stock Titan
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | VXRT Stock News - GuruFocus
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vaxart, Inc. Grants Equity Awards to New CFO Jeroen Grasman - Nasdaq
Vaxart Lures New CFO With Massive 1.35M Share Package: Inside the Compensation Deal - Stock Titan
Vaxart Approves Resolutions to Narrow Proposed Reverse - GlobeNewswire
Vaxart seeks approval for reverse stock split to retain Nasdaq listing By Investing.com - Investing.com South Africa
Vaxart Limits Reverse Stock Split To 1-for-20 In Response To Shareholder Feedback - Nasdaq
Vaxart Board Approves Reverse Split Proposal - TipRanks
Vaxart seeks approval for reverse stock split to retain Nasdaq listing - Investing.com Nigeria
0.92%
7.75%
자본화:
|
볼륨(24시간):